{"id":"d49ff4fb-0d7f-5be8-84fd-486b2d0234e4","stable_key":"53d9b98d-e3a0-5416-bc88-adbe42a8cb1b:curcumin-endoxifen-combination","predicate":"reduces","statement":"Endoxifen AUC fell 12.4% with curcumin plus piperine, p=0.02.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"68dbc265-5030-5e3c-ad35-6695d26e9cb7","mechanism_event_label":"The combination reduced exposure to tamoxifen's active metabolite.","subject":{"id":"fbaa1c70-6e65-5cd9-823b-7c74c49ccee4","slug":"curcumin-piperine-regimen","display_name":"Curcumin plus piperine regimen","entity_type_key":"chemical_species"},"object":{"id":"045cdbeb-de5d-514a-9da3-28cd2bbe4680","slug":"endoxifen-plasma-exposure","display_name":"Human endoxifen plasma exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"68dbc265-5030-5e3c-ad35-6695d26e9cb7","stable_key":"53d9b98d-e3a0-5416-bc88-adbe42a8cb1b:curcumin-endoxifen-combination-event","event_type":"observed_intervention","label":"The combination reduced exposure to tamoxifen's active metabolite.","description":"Endoxifen AUC fell 12.4% with curcumin plus piperine, p=0.02.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"53989c4c-d006-5dfc-a11b-8ac4ba48161c","slug":"tamoxifen","display_name":"Tamoxifen","entity_type_key":"small_molecule"},"role":"coadministered_drug","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"273b0b15-4e38-5918-9958-29dac49f6345","slug":"endoxifen","display_name":"Endoxifen / 4-hydroxy-N-desmethyltamoxifen","entity_type_key":"small_molecule"},"role":"measured_metabolite","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"0e625439-d093-5d1b-8713-dcfdafcf6811","slug":"curcumin","display_name":"Curcumin","entity_type_key":"small_molecule"},"role":"regimen_component","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"4d1060b9-e9b4-5ffd-88c2-21362c5d8491","slug":"piperine","display_name":"Piperine","entity_type_key":"small_molecule"},"role":"regimen_component","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"fbaa1c70-6e65-5cd9-823b-7c74c49ccee4","slug":"curcumin-piperine-regimen","display_name":"Curcumin plus piperine regimen","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"045cdbeb-de5d-514a-9da3-28cd2bbe4680","slug":"endoxifen-plasma-exposure","display_name":"Human endoxifen plasma exposure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/curcumin-research/30909366.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527\", \"start_char\": 0, \"end_char\": 1407, \"text_sha256\": \"43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Tamoxifen 20-30 mg/day; curcumin 1200 mg three times/day, with or without piperine 10 mg three times/day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small pharmacokinetic study, not a cancer recurrence trial. Piperine has independent effects; a particular CYP mechanism was not established.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Curcumin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"curcumin","display_name":"Curcumin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The combination reduced exposure to tamoxifen's active metabolite.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[curcumin-p30909366] Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. (2019). https://pubmed.ncbi.nlm.nih.gov/30909366/ DOI: 10.3390/cancers11030403","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Plasma drug and metabolite AUC","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"fde49e83-9476-57ae-a32d-4325fdd3c1ba","evidence_kind":"source_excerpt","locator":"Lines 970-981","start_line":970,"end_line":981,"excerpt":"### curcumin-endoxifen-combination\nEndoxifen AUC fell 12.4% with curcumin plus piperine, p=0.02.\nCondition category: normal\nnutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The combination reduced exposure to tamoxifen's active metabolite.\norganism: Homo sapiens\ntissue_or_cell_type: Plasma drug and metabolite AUC\nexperimental_model: Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients\nlimitations: Small pharmacokinetic study, not a cancer recurrence trial. Piperine has independent effects; a particular CYP mechanism was not established.\nexposure: Tamoxifen 20-30 mg/day; curcumin 1200 mg three times/day, with or without piperine 10 mg three times/day\nevidence_span: {\"source_cache\": \"artifacts/curcumin-research/30909366.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527\", \"start_char\": 0, \"end_char\": 1407, \"text_sha256\": \"43a5c2635c9fef8a31967689115b6152e81cf7d4d0f1687ffae113684c89d527\"}\n[curcumin-p30909366] Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. (2019). https://pubmed.ncbi.nlm.nih.gov/30909366/ DOI: 10.3390/cancers11030403","model_system":"Within-patient pharmacokinetic comparison in tamoxifen-treated breast cancer patients","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [curcumin-p30909366] Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. (2019). https://pubmed.ncbi.nlm.nih.gov/30909366/ DOI: 10.3390/cancers11030403","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"11d29ea9-3af1-5404-a68d-6f129e23edee","stable_key":"import-53d9b98d-e3a0-5416-bc88-adbe42a8cb1b","title":"Curcumin: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"6eeda0e6e358e0b19f73f554f8c027cb08015aa49d92a77bde36e3fb3ea1a41c","revision_id":"32e73d69-5445-5ace-b25d-5a4d3787aea5","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}